Melanie Meersch, Timo Mayerhöfer, Michael Joannidis
{"title":"Acute kidney injury subphenotyping and personalized medicine.","authors":"Melanie Meersch, Timo Mayerhöfer, Michael Joannidis","doi":"10.1097/MCC.0000000000001212","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review discusses novel concepts of acute kidney injury (AKI), including subphenotyping, which may facilitate the development of target treatment strategies for specific subgroups of patients to achieve precision medicine.</p><p><strong>Recent findings: </strong>AKI is a multifaceted syndrome with a major impact on morbidity and mortality. As efforts to identify treatment strategies have largely failed, it is becoming increasingly apparent that there are different subphenotypes that require different treatment strategies. Various ways of subphenotyping AKI have been investigated, including the use of novel renal biomarkers, machine learning and artificial intelligence, some of which have already been implemented in the clinical setting. Thus, novel renal biomarkers have been recommended for inclusion in new definition criteria for AKI and for the use of biomarker bundled strategies for the prevention of AKI. Computational models have been explored and require future research.</p><p><strong>Summary: </strong>Subphenotyping of AKI may provide a new understanding of this syndrome and guide targeted treatment strategies in order to improve patient outcomes.</p>","PeriodicalId":10851,"journal":{"name":"Current Opinion in Critical Care","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Critical Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCC.0000000000001212","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: This review discusses novel concepts of acute kidney injury (AKI), including subphenotyping, which may facilitate the development of target treatment strategies for specific subgroups of patients to achieve precision medicine.
Recent findings: AKI is a multifaceted syndrome with a major impact on morbidity and mortality. As efforts to identify treatment strategies have largely failed, it is becoming increasingly apparent that there are different subphenotypes that require different treatment strategies. Various ways of subphenotyping AKI have been investigated, including the use of novel renal biomarkers, machine learning and artificial intelligence, some of which have already been implemented in the clinical setting. Thus, novel renal biomarkers have been recommended for inclusion in new definition criteria for AKI and for the use of biomarker bundled strategies for the prevention of AKI. Computational models have been explored and require future research.
Summary: Subphenotyping of AKI may provide a new understanding of this syndrome and guide targeted treatment strategies in order to improve patient outcomes.
综述的目的:本综述讨论了急性肾损伤(AKI)的新概念,包括亚表型,这可能有助于为特定亚组患者制定目标治疗策略,从而实现精准医疗:急性肾损伤是一种多方面的综合征,对发病率和死亡率有重大影响。由于确定治疗策略的努力大多以失败告终,人们越来越清楚地认识到,不同的亚型需要不同的治疗策略。目前已研究出多种对 AKI 进行亚型分型的方法,包括使用新型肾脏生物标志物、机器学习和人工智能,其中一些方法已在临床环境中实施。因此,已建议将新型肾脏生物标志物纳入新的 AKI 定义标准,并使用生物标志物捆绑策略来预防 AKI。小结:对 AKI 进行亚表型分析可使人们对这一综合征有新的认识,并指导有针对性的治疗策略,从而改善患者的预后。
期刊介绍:
Current Opinion in Critical Care delivers a broad-based perspective on the most recent and most exciting developments in critical care from across the world. Published bimonthly and featuring thirteen key topics – including the respiratory system, neuroscience, trauma and infectious diseases – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.